In what researchers are calling a potentially transformative development for breast cancer care, an experimental vaccine targeting triple-negative breast cancer (TNBC) has shown encouraging results in ...
Trodelvy showed fewer severe side effects and required fewer dose reductions or discontinuations compared to chemotherapy in TNBC patients. Common side effects, such as neutropenia and diarrhea, were ...
Researchers from Nankai University and collaborating institutions have identified a novel proteolysis targeting chimera (PROTAC) molecule that effectively and selectively degrades multiple ...
Trodelvy showed fewer severe side effects, such as neutropenia and diarrhea, compared to chemotherapy in untreated TNBC patients. The study's primary endpoint, progression-free survival, favored ...
Triple-negative breast cancer (TNBC) is a highly aggressive subtype affecting 15%-20% of breast cancer patients. TNBC patients harboring breast cancer susceptibility gene 1/2 (BRCA1/2) mutations have ...
Researchers at The University of Texas MD Anderson Cancer Center have characterized cancer cell-specific features in the tumor microenvironment (TME) of early-stage triple-negative breast cancer (TNBC ...
Results of two Chinese phase 3 trials presented at this year’s San Antonio Breast Cancer Symposium (SABCS) 2025 provide strong support for adjuvant carboplatin in early-stage triple-negative breast ...
Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (”TNBC”) show encouraging antitumor activity for investigational therapy pumitamig (BNT327/BMS986545) plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results